Amb motiu del tancament d'estiu, la validació de documents es reprendrà a partir del 28 d'agost de 2026. Disculpeu les molèsties.
Con motivo del cierre de verano, la validación de documentos se reanudará a partir del 28 de agosto de 2026. Disculpad las molestias
Due to the summer closure, document validation will resume starting August 28, 2026. We apologize for any inconvenience.

Fitxers

666315.pdf (1.25 MB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2014-05-28

Llicència de publicació

cc-by (c) Cordero Coma, Miguel et al., 2014
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/113335

Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.1155/2014/717598

Resum

Objective. To evaluate, in three Spanish tertiary referral centres, the short-term safety and efficacy of golimumab (GLM) for treatment of immune-mediated uveitis resistant to previous immunosuppressive therapy. Methods. Nonrandomized retrospective interventional case series. Thirteen patients with different types of uveitis that were resistant to treatment with at least 2 previous immunosuppressors were included in this study. All included patients were treated with GLM (50 mg every four weeks) during at least 6 months. Clinical evaluation and treatment-related side effects were assessed at least four times in all included patients. Results. Eight men and 5 women (22 affected eyes) with a median age of 30 years (range 20-38) and active immune-mediated uveitides were studied. GLM was used in combination with conventional immunosuppressors in 7 patients (53.8%). GLM therapy achieved complete control of inflammation in 12/13 patients (92.3%) after six months of treatment. There was a statistically significant improvement in mean BCVA (0.60 versus 0.68, P - 0.009) and mean 1 mm central retinal thickness (317 versus 261.2 mu, P -0.05) at the six-month endpoint when compared to basal values. No major systemic adverse effects associated with GLM therapy were observed. Conclusions. GLM is a new and promising therapeutic option for patients with severe and refractory uveitis.

Matèries

Uveïtis, Oftalmologia

Matèries (anglès)

Uveitis, Ophthalmology

Citació

Col·leccions

Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Citació

CORDERO COMA, Miguel, et al. Golimumab as rescue therapy for refractory immune-mediated uveitis: a three-center experience. Mediators of Inflammation. 2014. Vol. 2014. ISSN 0962-9351. [consulted: 4 of August of 2026]. Available at: https://hdl.handle.net/2445/113335

Exportar metadades

JSON - METS

Compartir registre